Identification

Name
Paramethasone
Accession Number
DB01384
Type
Small Molecule
Groups
Approved
Description

A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)

Structure
Thumb
Synonyms
  • Dillar
Product Ingredients
IngredientUNIICASInChI Key
Paramethasone acetate8X50N88ZDP1597-82-6HYRKAAMZBDSJFJ-LFDBJOOHSA-N
International/Other Brands
Haldrone
Categories
UNII
VFC6ZX3584
CAS number
53-33-8
Weight
Average: 392.4611
Monoisotopic: 392.199902243
Chemical Formula
C22H29FO5
InChI Key
MKPDWECBUAZOHP-AFYJWTTESA-N
InChI
InChI=1S/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1S,2R,8S,10S,11S,13R,14R,15S,17S)-8-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone.

Structured Indications
Not Available
Pharmacodynamics

Paramethasone is a glucocorticoid with the general properties of corticosteroids. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Mechanism of action

Glucocorticoids such as paramethasone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Paramethasone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

80%

Metabolism

Hepatic.

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include inhibition of bone formation, suppression of calcium absorption delayed wound healing, immune suppression, and hyperglycemia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Paramethasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Paramethasone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Paramethasone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Paramethasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Paramethasone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Paramethasone.Approved, Withdrawn
AldesleukinParamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Paramethasone can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Paramethasone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Paramethasone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Paramethasone.Experimental
AloglutamolThe bioavailability of Paramethasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Paramethasone.Experimental
AluminiumThe bioavailability of Paramethasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Paramethasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Paramethasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Paramethasone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Paramethasone.Approved
AmiodaroneThe metabolism of Paramethasone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BParamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Paramethasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Paramethasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Paramethasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Paramethasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Paramethasone.Approved, Investigational
AprepitantThe serum concentration of Paramethasone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Paramethasone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Paramethasone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Paramethasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Paramethasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Paramethasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Paramethasone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Paramethasone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Paramethasone.Experimental
BendroflumethiazideParamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Paramethasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Paramethasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Paramethasone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Paramethasone.Experimental
Bismuth SubcitrateThe bioavailability of Paramethasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Paramethasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Paramethasone can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Paramethasone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Paramethasone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Paramethasone.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paramethasone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Paramethasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Paramethasone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Paramethasone.Experimental
BumetanideParamethasone may increase the hypokalemic activities of Bumetanide.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paramethasone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Paramethasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Paramethasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Paramethasone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideParamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Paramethasone can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Paramethasone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Paramethasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Paramethasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Paramethasone.Approved, Investigational
CeritinibThe serum concentration of Paramethasone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Paramethasone.Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Paramethasone.Approved, Vet Approved
ChlorothiazideParamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Paramethasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneParamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Paramethasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe metabolism of Paramethasone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Paramethasone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Paramethasone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Paramethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Paramethasone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Paramethasone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Paramethasone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Paramethasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Paramethasone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Paramethasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Paramethasone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Paramethasone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Paramethasone.Investigational
CyclopenthiazideParamethasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Paramethasone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Paramethasone.Investigational
DabrafenibThe serum concentration of Paramethasone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Paramethasone can be increased when it is combined with Daidzein.Experimental
DarunavirThe metabolism of Paramethasone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Paramethasone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Paramethasone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Paramethasone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Paramethasone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Paramethasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Paramethasone.Approved, Vet Approved
DienestrolThe serum concentration of Paramethasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Paramethasone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Paramethasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Paramethasone.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Paramethasone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Paramethasone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Paramethasone.Experimental
DihydroergotamineThe metabolism of Paramethasone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneParamethasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Paramethasone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Paramethasone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Paramethasone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Paramethasone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Paramethasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Paramethasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Paramethasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Paramethasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Paramethasone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Paramethasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Paramethasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Paramethasone.Approved
EquolThe serum concentration of Paramethasone can be increased when it is combined with Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paramethasone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paramethasone.Approved
ErythromycinThe metabolism of Paramethasone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Paramethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Paramethasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Paramethasone can be increased when it is combined with Estrone.Approved
Etacrynic acidParamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Paramethasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Paramethasone.Experimental
Ethinyl EstradiolThe serum concentration of Paramethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Paramethasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Paramethasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Paramethasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Paramethasone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Paramethasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Paramethasone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Paramethasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Paramethasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Paramethasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Paramethasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Paramethasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Paramethasone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Paramethasone.Approved, Withdrawn
FluconazoleThe metabolism of Paramethasone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Paramethasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Paramethasone.Experimental
FluoxymesteroneParamethasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Paramethasone.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Paramethasone.Approved
FluvoxamineThe metabolism of Paramethasone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Paramethasone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Paramethasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Paramethasone can be increased when combined with Fosphenytoin.Approved
FurosemideParamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Paramethasone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Paramethasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Paramethasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Paramethasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Paramethasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Paramethasone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Paramethasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Paramethasone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Paramethasone.Experimental
HexestrolThe serum concentration of Paramethasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Paramethasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Paramethasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.Approved, Investigational
HydrochlorothiazideParamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideParamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Paramethasone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Paramethasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Paramethasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Paramethasone.Approved
IdelalisibThe serum concentration of Paramethasone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Paramethasone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Paramethasone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Paramethasone.Approved
IndapamideParamethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Paramethasone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Paramethasone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Paramethasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Paramethasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Paramethasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Paramethasone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Paramethasone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Paramethasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Paramethasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Paramethasone.Withdrawn
IsradipineThe metabolism of Paramethasone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Paramethasone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Paramethasone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Paramethasone.Experimental
KetoconazoleThe metabolism of Paramethasone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Paramethasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Paramethasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Paramethasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Paramethasone.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Paramethasone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Paramethasone.Experimental
LopinavirThe metabolism of Paramethasone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Paramethasone.Approved
LovastatinThe metabolism of Paramethasone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Paramethasone.Approved
LuliconazoleThe serum concentration of Paramethasone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Paramethasone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Paramethasone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Paramethasone.Illicit, Withdrawn
MagaldrateThe bioavailability of Paramethasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Paramethasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Paramethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Paramethasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Paramethasone.Approved
Magnesium silicateThe bioavailability of Paramethasone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Paramethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Paramethasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Paramethasone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Paramethasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Paramethasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Paramethasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Paramethasone.Approved
MesteroloneParamethasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Paramethasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Paramethasone.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Paramethasone.Experimental
MethallenestrilThe serum concentration of Paramethasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Paramethasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideParamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Paramethasone is combined with Methyl salicylate.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Paramethasone.Approved
MethyltestosteroneParamethasone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Paramethasone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Paramethasone is combined with Metoclopramide.Approved, Investigational
MetolazoneParamethasone may increase the hypokalemic activities of Metolazone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Paramethasone.Experimental
MifepristoneThe serum concentration of Paramethasone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Paramethasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Paramethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Paramethasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Paramethasone.Experimental
MoxestrolThe serum concentration of Paramethasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Paramethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paramethasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Paramethasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Paramethasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Paramethasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Paramethasone is combined with Nalidixic Acid.Approved
NandroloneParamethasone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Paramethasone.Approved, Vet Approved
NefazodoneThe metabolism of Paramethasone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Paramethasone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Paramethasone.Approved
NetupitantThe serum concentration of Paramethasone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Paramethasone can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Paramethasone.Approved
NicorandilThe risk or severity of adverse effects can be increased when Paramethasone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Paramethasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Paramethasone.Approved
NilotinibThe metabolism of Paramethasone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Paramethasone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Paramethasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Paramethasone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paramethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Paramethasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Paramethasone.Vet Approved
OsimertinibThe serum concentration of Paramethasone can be increased when it is combined with Osimertinib.Approved
OxandroloneParamethasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Paramethasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Paramethasone is combined with Oxolinic acid.Experimental
OxymetholoneParamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Paramethasone.Withdrawn
PalbociclibThe serum concentration of Paramethasone can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Paramethasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Paramethasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Paramethasone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Paramethasone can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Paramethasone.Approved, Vet Approved, Withdrawn
PhenobarbitalThe metabolism of Paramethasone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Paramethasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Paramethasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Paramethasone.Approved, Investigational
PhenytoinThe metabolism of Paramethasone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paramethasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pipemidic acid.Experimental
PiretanideParamethasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Paramethasone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Paramethasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Paramethasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Paramethasone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Paramethasone.Approved
Polyestradiol phosphateThe serum concentration of Paramethasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideParamethasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Paramethasone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Paramethasone.Experimental
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Paramethasone.Approved
PrimidoneThe metabolism of Paramethasone can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Paramethasone.Experimental
PromestrieneThe serum concentration of Paramethasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Paramethasone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Paramethasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Paramethasone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Paramethasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Paramethasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneParamethasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe metabolism of Paramethasone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Paramethasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Paramethasone.Experimental, Investigational
RifabutinThe metabolism of Paramethasone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Paramethasone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Paramethasone can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rindopepimut.Investigational
RitonavirThe metabolism of Paramethasone can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Paramethasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rosoxacin.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Paramethasone.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Paramethasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Paramethasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Paramethasone.Approved
SaquinavirThe metabolism of Paramethasone can be decreased when combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Paramethasone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Paramethasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Paramethasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Paramethasone.Investigational
SildenafilThe metabolism of Paramethasone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Paramethasone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Paramethasone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Paramethasone.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Paramethasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Paramethasone.Investigational
St. John's WortThe serum concentration of Paramethasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololParamethasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Paramethasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Paramethasone.Approved
SulfisoxazoleThe metabolism of Paramethasone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Paramethasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Paramethasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Paramethasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Paramethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Paramethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Paramethasone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Paramethasone.Withdrawn
TelithromycinThe metabolism of Paramethasone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Paramethasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Paramethasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Paramethasone.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Paramethasone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Paramethasone.Approved
TestosteroneParamethasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Paramethasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Paramethasone.Approved
TiboloneThe serum concentration of Paramethasone can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Paramethasone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Paramethasone.Investigational
TocilizumabThe serum concentration of Paramethasone can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Paramethasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Paramethasone.Approved
TorasemideParamethasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Paramethasone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Paramethasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Paramethasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideParamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Paramethasone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Paramethasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Paramethasone.Experimental
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Paramethasone.Investigational, Withdrawn
VenlafaxineThe metabolism of Paramethasone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Paramethasone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Paramethasone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinParamethasone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Paramethasone.Approved
ZeranolThe serum concentration of Paramethasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Paramethasone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Paramethasone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Paramethasone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Paramethasone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15462
KEGG Compound
C07413
PubChem Compound
5875
PubChem Substance
46504651
ChemSpider
5664
ChEBI
7922
ChEMBL
CHEMBL1579
Therapeutic Targets Database
DAP000422
PharmGKB
PA164777035
Wikipedia
Paramethasone
ATC Codes
H02AB05 — Paramethasone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.145 mg/mLALOGPS
logP1.51ALOGPS
logP1.3ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.79 m3·mol-1ChemAxon
Polarizability40.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.971
Caco-2 permeable+0.747
P-glycoprotein substrateSubstrate0.7725
P-glycoprotein inhibitor INon-inhibitor0.7629
P-glycoprotein inhibitor IINon-inhibitor0.9002
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.8789
CYP450 2D6 substrateNon-substrate0.9031
CYP450 3A4 substrateSubstrate0.6991
CYP450 1A2 substrateNon-inhibitor0.9313
CYP450 2C9 inhibitorNon-inhibitor0.9254
CYP450 2D6 inhibitorNon-inhibitor0.939
CYP450 2C19 inhibitorNon-inhibitor0.9234
CYP450 3A4 inhibitorNon-inhibitor0.7563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8979
Ames testNon AMES toxic0.8509
CarcinogenicityNon-carcinogens0.9232
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3293 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.6022
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 7 more
Substituents
21-hydroxysteroid / Progestogin-skeleton / 20-oxosteroid / Pregnane-skeleton / Halo-steroid / 3-oxo-delta-1,4-steroid / 6-halo-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid
show 21 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
fluorinated steroid (CHEBI:7922)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  3. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953]
  4. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198]
  5. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
  6. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on July 06, 2007 14:34 / Updated on October 02, 2017 04:58